Nanotechnology based approaches for detection and delivery of microRNA in healthcare and crop protection

Chaudhary, Vrantika; Jangra, Sumit; Yadav, Neelam

doi:10.1186/s12951-018-0368-8

Cited by 74 publications

(56 citation statements)

References 230 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inorganic Nanoparticles (NPs) have striking electrical and optical properties, as well as high biocompatibility [101]. Among the most cited and characterized inorganic NPs adopted for miRNA delivery, gold NPs and mesoporous silica NPs are noteworthy [102]. However, cerium oxide NPs can also be a valid alternative, due to their intrinsic antioxidant properties [103].…”

Section: Inorganic Nanoparticlesmentioning

confidence: 99%

See 1 more Smart Citation

Targeting microRNAs as a Therapeutic Strategy to Reduce Oxidative Stress in Diabetes

Grieco

Brusco

Licata

et al. 2019

IJMS

View full text Add to dashboard Cite

Diabetes mellitus is a group of heterogeneous metabolic disorders characterized by chronic hyperglycaemia as a consequence of pancreatic β cell loss and/or dysfunction, also caused by oxidative stress. The molecular mechanisms involved inβ cell dysfunction and in response to oxidative stress are also regulated by microRNAs (miRNAs). miRNAs are a class of negative gene regulators, which modulate pathologic mechanisms occurring in diabetes and its complications. Although several pharmacological therapies specifically targeting miRNAs have already been developed and brought to the clinic, most previous miRNA-based drug delivery methods were unable to target a specific miRNA in a single cell type or tissue, leading to important off-target effects. In order to overcome these issues, aptamers and nanoparticles have been described as non-cytotoxic vehicles for miRNA-based drug delivery. These approaches could represent an innovative way to specifically target and modulate miRNAs involved in oxidative stress in diabetes and its complications. Therefore, the aims of this review are: (i) to report the role of miRNAs involved in oxidative stress in diabetes as promising therapeutic targets; (ii) to shed light onto the new delivery strategies developed to modulate the expression of miRNAs in diseases.

show abstract

Section: Inorganic Nanoparticlesmentioning

confidence: 99%

“…miRNAs can easily be transferred to cells and tissues using liposomes [102,125]. Liposomes are composed of cationic lipids structurally characterized by an hydrophobic moiety and a positively charged cationic head; nucleic acids naturally binds to liposomes through their phosphate-generated negative charge [126].…”

Section: Organic Nanoparticles (Nps)mentioning

confidence: 99%

Targeting microRNAs as a Therapeutic Strategy to Reduce Oxidative Stress in Diabetes

Grieco

Brusco

Licata

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Conjugation to cell‐penetrating peptides enables crossing of cell and endosomal membranes. With the development of nanotechnology, nanocarriers have recently become popular for miRNA delivery to enhance cellular uptake and delivery effectiveness as well as reduce toxicity . Nanocarriers are safe and require simple manufacturing.…”

Section: The Utility Of Mirnas As New Therapeutic Targetsmentioning

confidence: 99%

MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: An update

et al. 2019

View full text Add to dashboard Cite

Diabetic kidney disease (DKD) is a life‐limiting condition characterized by progressive and irreversible loss of renal function. Currently, the estimated glomerular filtration rate (eGFR) and albuminuria are used as key markers to define DKD. However, they may not accurately indicate the degree of renal dysfunction and injury. Current therapeutic approaches for DKD, including attainment of blood pressure goals, optimal control of blood glucose and lipid levels, and the use of agents to block the renin‐angiotensin‐aldosterone system (RAAS) can only slow the progression of DKD. Hence, early diagnosis and innovative strategies are needed to both prevent and treat DKD. In recent years, a novel class of noncoding RNA, microRNAs (miRNAs) are reported to be involved in all biological processes, including cellular proliferation, apoptosis, and differentiation. miRNAs are small noncoding RNAs that regulate gene expression by posttranscriptional and epigenetic mechanisms. They are found to be in virtually all body fluids and used successfully as biomarkers for various diseases. Urinary miRNAs correlate with clinical and histologic parameters in DKD and differential urinary miRNA expression patterns have been reported. Kidney fibrosis is the common end stage of various CKD including DKD. Transforming growth factor‐β(TGF‐β) is regarded as the master regulator of kidney fibrosis, which is likely at least in part through regulating miRNA expression. miRNA are widely involved in the progression of DKD via many molecular mechanisms. In this review, the involvement of miRNA in fibrosis, inflammation, hypertrophy, autophagy, endoplasmic reticulum (ER) stress, oxidative stress, insulin resistance, and podocyte injury will be discussed, as these mechanisms are believed to offer new therapeutic targets that can be exploited to develop important treatments for DKD over the next decade.

show abstract

“…Despite the therapeutic potential of miRs, their delivery remains challenging, due to undesired off-target effects, hindered cell uptake, and short circulation half-life ( 25 ). Synthetic nanoparticles (NPs) mediate specific cell uptake and prevent miR clearance ( 26 ). In preclinical models, effective miR supply was obtained via neutral lipid emulsion-based approach for miRs of the let-7 family, as well as neutral liposomes and synthetic polyethylenimine-based nanocarriers for miR-145.…”

Section: Introductionmentioning

confidence: 99%

microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy

et al. 2020

View full text Add to dashboard Cite

Immunotherapy with immune checkpoint inhibitors can achieve long-term tumor control in subsets of patients. However, its effect can be blunted by myeloid-induced resistance mechanisms. Myeloid cells are highly plastic and physiologically devoted to wound healing and to immune homeostasis maintenance. In cancer, their physiological activities can be modulated, leading to an expansion of pro-inflammatory and immunosuppressive cells, the myeloid-derived suppressor cells (MDSCs), with detrimental consequences. The involvement of MDSCs in tumor development and progression has been widely investigated and MDSC-induced immunosuppression is acknowledged as a mechanism hindering effective immune checkpoint blockade. Small non-coding RNA molecules, the microRNAs (miRs), contribute to myeloid cell regulation at different levels, comprising metabolism and function, as well as their skewing to a MDSC phenotype. miR expression can be indirectly induced by cancer-derived factors or through direct miR import via extracellular vesicles. Due to their structural stability and their presence in body fluids miRs represent promising predictive biomarkers of resistance, as we recently found by investigating plasma samples of melanoma patients undergoing immune checkpoint blockade. Dissection of the miR-driven involved mechanisms would pave the way for the identification of new druggable targets. Here, we discuss the role of these miRs in shaping myeloid resistance to immunotherapy with a special focus on immunosuppression and immune escape.

show abstract

Nanotechnology based approaches for detection and delivery of microRNA in healthcare and crop protection

Cited by 74 publications

References 230 publications

Targeting microRNAs as a Therapeutic Strategy to Reduce Oxidative Stress in Diabetes

Targeting microRNAs as a Therapeutic Strategy to Reduce Oxidative Stress in Diabetes

MicroRNA as novel biomarkers and therapeutic targets in diabetic kidney disease: An update

microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy

Contact Info

Product

Resources

About